Roche and Blueprint Medicines Corporation, a precision therapy company headquartered in Cambridge, MA, announced on July 14, 2020 that they are entering into a licensing and collaboration agreement for the co-commercialization rights to pralsetinib, Blueprint Medicine s investigational, once-dai
